These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 35449580)

  • 41. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
    Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
    Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CRISPR-Cas9 system: a novel and promising era of genotherapy for beta-hemoglobinopathies, hematological malignancy, and hemophilia.
    Alayoubi AM; Khawaji ZY; Mohammed MA; Mercier FE
    Ann Hematol; 2024 Jun; 103(6):1805-1817. PubMed ID: 37736806
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CRISPR/Cas9-Mediated Customizing Strategies for Adoptive T-Cell Therapy.
    Park H; Kang YK; Shim G
    Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543240
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.
    Ghaffari S; Khalili N; Rezaei N
    J Exp Clin Cancer Res; 2021 Aug; 40(1):269. PubMed ID: 34446084
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
    Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
    Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CRISPR/Cas-based CAR-T cells: production and application.
    Song P; Zhang Q; Xu Z; Shi Y; Jing R; Luo D
    Biomark Res; 2024 May; 12(1):54. PubMed ID: 38816881
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system.
    Hajifathali A; Lasemi MV; Mehravar M; Moshari MR; Alizadeh AM; Roshandel E
    Hematol Transfus Cell Ther; 2024; 46(1):58-66. PubMed ID: 37451978
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Can genetic engineering-based methods for gene function identification be eclipsed by genome editing in plants? A comparison of methodologies.
    Amritha PP; Shah JM
    Mol Genet Genomics; 2021 May; 296(3):485-500. PubMed ID: 33751237
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment.
    Akram F; Haq IU; Sahreen S; Nasir N; Naseem W; Imitaz M; Aqeel A
    Technol Cancer Res Treat; 2022; 21():15330338221132078. PubMed ID: 36254536
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Overcoming tumor resistance mechanisms in CAR-NK cell therapy.
    Valeri A; García-Ortiz A; Castellano E; Córdoba L; Maroto-Martín E; Encinas J; Leivas A; Río P; Martínez-López J
    Front Immunol; 2022; 13():953849. PubMed ID: 35990652
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CRISPR-Cas9-Mediated TIM3 Knockout in Human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells.
    Morimoto T; Nakazawa T; Matsuda R; Nishimura F; Nakamura M; Yamada S; Nakagawa I; Park YS; Tsujimura T; Nakase H
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800561
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
    Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Ouji N; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
    J Exp Clin Cancer Res; 2023 Aug; 42(1):205. PubMed ID: 37563692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.
    Grote S; Ureña-Bailén G; Chan KC; Baden C; Mezger M; Handgretinger R; Schleicher S
    Cells; 2021 Apr; 10(5):. PubMed ID: 33925968
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetic Manipulation Approaches to Enhance the Clinical Application of NK Cell-Based Immunotherapy.
    Maia A; Tarannum M; Romee R
    Stem Cells Transl Med; 2024 Mar; 13(3):230-242. PubMed ID: 38142460
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long Terminal Repeat CRISPR-CAR-Coupled "Universal" T Cells Mediate Potent Anti-leukemic Effects.
    Georgiadis C; Preece R; Nickolay L; Etuk A; Petrova A; Ladon D; Danyi A; Humphryes-Kirilov N; Ajetunmobi A; Kim D; Kim JS; Qasim W
    Mol Ther; 2018 May; 26(5):1215-1227. PubMed ID: 29605708
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Principles, Applications, and Biosafety of Plant Genome Editing Using CRISPR-Cas9.
    El-Mounadi K; Morales-Floriano ML; Garcia-Ruiz H
    Front Plant Sci; 2020; 11():56. PubMed ID: 32117392
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
    Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
    Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CRISPR-Based Editing Techniques for Genetic Manipulation of Primary T Cells.
    Kotowski M; Sharma S
    Methods Protoc; 2020 Nov; 3(4):. PubMed ID: 33217926
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity.
    Lee DH; Ahn H; Sim HI; Choi E; Choi S; Jo Y; Yun B; Song HK; Oh SJ; Denda-Nagai K; Park CS; Irimura T; Park Y; Jin HS
    J Exp Clin Cancer Res; 2023 Oct; 42(1):272. PubMed ID: 37858248
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A glance at genome editing with CRISPR-Cas9 technology.
    Barman A; Deb B; Chakraborty S
    Curr Genet; 2020 Jun; 66(3):447-462. PubMed ID: 31691023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.